{"entity":{"id":"nct06772623","kind":"trial","name":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","aka":[],"tldr":"A phase 1/2 trial of Telisotuzumab adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed and Cisplatin in non-small-cell lung cancer, run by AbbVie, now recruiting.","summary":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations is a phase 1/2 interventional study registered as NCT06772623 by AbbVie, with 252 participants planned, started 2025-03-06 and due to reach its primary completion in 2027-11. Interventions recorded: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed and Cisplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06772623","url":"https://clinicaltrials.gov/study/NCT06772623"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["telisotuzumab-adizutecan","budigalimab","pembrolizumab","carboplatin","pemetrexed","cisplatin"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06772623","phase":"1/2","setting":"An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations","sponsor":"AbbVie","enrolled":252,"outcomes":[]},"route":"/trials/nct06772623/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"budigalimab","kind":"drug","name":"Budigalimab","route":"/drugs/budigalimab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}